Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 5, 2014, Pages 341-348

  Lee, Young Ho ^a   Bae, Sang Cheol ^b   Song, Gwan Gyu ^a  

^a College of Medicine   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ALANINE; PROLINE;

ARTICLE; ASIAN; CODON USAGE; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS;

ALANINE; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE;

EID: 84899798690     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0503     Document Type: Article

References (34)

1. Beaven SW, Tontonoz P (2006) Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 57:313-329
2. Bhatt SP, Nigam P, Misra A, et al. (2013) Association of peroxisome proliferator activated receptor-gamma gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. Gene 512:143-147
3. Bowes J, Ho P, Flynn E, et al. (2012) Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. Ann Rheum Dis 71:313-314
4. Brunt EM (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7:195-203
5. Butt C, Gladman D, Rahman P (2006) PPAR-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol 33:1631-1633
6. Cao CY, Li YY, Zhou YJ, et al. (2012) The C-681G polymorphism of the PPAR-gamma gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med 227:253-262
7. Choi SJ, Rho YH, Ji JD, et al. (2006) Genome scan metaanalysis of rheumatoid arthritis. Rheumatology (Oxford) 45:166-170
8. Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
9. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
10. Dimitrova-Shumkovska J, Veenman L, Ristoski T, et al. (2010) Chronic high fat, high cholesterol supplementation decreases 18 kDa Translocator Protein binding capacity in association with increased oxidative stress in rat liver and aorta. Food Chem Toxicol 48:910-921
11. Dongiovanni P, Rametta R, Fracanzani AL, et al. (2010) Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol 10:102
12. Dongiovanni P, Valenti L (2013) Peroxisome proliferatoractivated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? PPAR Res 2013:452061
13. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
14. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533-1537
15. El-Sohemy A, Cornelis MC, Park YW, Bae SC (2006) Catalase and PPARgamma2 genotype and risk of rheumatoid arthritis in Koreans. Rheumatol Int 26:388-392
16. Gavrilova O, Haluzik M, Matsusue K, et al. (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276
17. Gawrieh S, Marion MC, Komorowski R, et al. (2012) Genetic variation in the peroxisome proliferator activated receptorgamma gene is associated with histologically advanced NAFLD. Dig Dis Sci 57:952-957
18. Gupta AC, Chaudhory AK, Sukriti, Pande C, Sakhuja P, et al. (2010) Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in nonalcoholic fatty liver disease patients. Hepatol Int 5:575-580
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558
20. Hui Y, Yu-Yuan L, Yu-Qiang N, et al. (2008) Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 28:385-392
21. Jalil SF, Ahmed I, Gauhar Z, et al. (2013) Association of Pro12Ala (rs1801282) variant of PPAR gamma with Rheumatoid Arthritis in a Pakistani population. Rheumatol Int [Epub ahead of print]; DOI: 10.1007/s00296-013-2768-2
22. Knouff C, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25:899-918
23. Lee YH, Rho YH, Choi SJ, et al. (2006) Association of TNFalpha-308 G/A polymorphism with responsiveness to TNFalpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 27:157-161
24. Lee YH, Witte T, Momot T, et al. (2005) The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52:3966-3974
25. Luo W, Cao J, Li J, He W (2008) Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. Exp Gerontol 43:154-163
26. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219
27. Nath SK, Harley JB, Lee YH (2005) Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 118:225-234
28. Pan XF, Song XB, Wang LL, et al. (2009) [Association of the Pro12Ala polymorphism in peroxisome proliferators activated receptor-gamma gene with rheumatoid arthritis in Sichuan Province of China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26:87-90
29. Rey JW, Noetel A, Hardt A, et al. (2010) Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 in patients with fatty liver diseases. World J Gastroenterol 16:5830-5837
30. Terauchi Y (2007) [PPARgamma and metabolic syndrome]. Rinsho Byori 55:447-451
31. Thamer C, Haap M, Volk A, et al. (2002) Evidence for greater oxidative substrate flexibility in male carriers of the Pro 12 Ala polymorphism in PPARgamma2. Horm Metab Res 34:132-136
32. Tonjes A, Stumvoll M (2007) The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care 10:410-414
33. Yang Z, Wen J, Li Q, et al. (2012) PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Mol Cell Endocrinol 348:255-259
34. Zhou YJ, Li YY, Nie YQ, et al. (2010) Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol 25: 772-777.